AI for biomedical research
Open for applications
AI for biomedical research
201-500 employees
Open for applications
201-500 employees
To exponentially increase the speed and quality of life-saving research by empowering scientists with the world's most advanced biomedical artificial intelligence.
Over the past decade, the cost of bringing a drug to market has increased exponentially. But the number of drugs approved has stayed stagnant, leading to a decline in research productivity. Through development of AI-assisted software, BenchSci has allowed scientists to rapidly compute data from scientific journals and product catalogues to dramatically reduce these inefficiencies in the R&D process.
The company offers a lateral solution to traditional, manual data analysis to allow for data leveraging. Plus an automated, comprehensive overview of existing relevant research. These methods have made BenchSci a forerunner in the drug development industry; the company's software is used by leading pharmaceutical companies.
BenchSci continues to invest in its machine learning technology, and in 2023 launched ASCEND. This is software that extracts experimental evidence from internal and external sources to help improve the hit rate of drug trials. It has also raised considerable funds, the latest of which is supporting the expansion of the platform.
Steph
Company Specialist at Welcome to the Jungle
May 2023
$67.2m
SERIES D
Jan 2022
$44.6m
SERIES C
South Core, Toronto, ON
Dr. Elvis Wianda
(Co-Founder & Chief Data Officer)Obtained a PhD studying Health & Medical Physics at the University of Toronto before joining BenchSci.
Dr. Tom Leung
(Co-Founder & CSO)Previously held roles within the University of Toronto as a Research Assistant and Postdoctoral Fellow.
Liran Belenzon
(Co-Founder & CEO)Previously co-founded and held role as CEO at companies including Standy and Biz-Coupon. Currently a CDL Associate at Creative Destruction Lab.
Share this job
View 12 more jobs at BenchSci